Kronos Bio, Inc. financial data

Symbol
KRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
1300 S. El Camino Real, Suite 400, San Mateo, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 800 % -15.3%
Debt-to-equity 34 % +25.6%
Return On Equity -64.6 % -15.4%
Return On Assets -48.2 % -9.45%
Operating Margin -944 % +70.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.3M shares +3.47%
Common Stock, Shares, Outstanding 60.3M shares +3.7%
Entity Public Float 48.3M USD -76.4%
Common Stock, Value, Issued 60K USD +3.45%
Weighted Average Number of Shares Outstanding, Basic 60.3M shares +3.72%
Weighted Average Number of Shares Outstanding, Diluted 60.3M shares +3.72%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.86M USD +146%
Research and Development Expense 60.8M USD -31.6%
General and Administrative Expense 31.7M USD -21.4%
Operating Income (Loss) -93.1M USD +27.4%
Nonoperating Income (Expense) 7.49M USD -17.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -85.6M USD +28.2%
Earnings Per Share, Basic -1.43 USD/shares +31.3%
Earnings Per Share, Diluted -1.43 USD/shares +31.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75M USD +30.1%
Cash, Cash Equivalents, and Short-term Investments 248M USD -27%
Assets, Current 128M USD -33.2%
Property, Plant and Equipment, Net 7.23M USD -36%
Operating Lease, Right-of-Use Asset 12.3M USD -40%
Other Assets, Noncurrent 577K USD -40.5%
Assets 150M USD -37%
Accounts Payable, Current 1.28M USD -68.7%
Employee-related Liabilities, Current 2.25M USD -39.3%
Accrued Liabilities, Current 4.45M USD -35.8%
Contract with Customer, Liability, Current 5.16M USD -39.9%
Liabilities, Current 15.4M USD -40.1%
Contract with Customer, Liability, Noncurrent 975K USD -86.9%
Operating Lease, Liability, Noncurrent 22.5M USD -14.2%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 38.9M USD -34.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 24K USD
Retained Earnings (Accumulated Deficit) -569M USD -17.7%
Stockholders' Equity Attributable to Parent 111M USD -37.8%
Liabilities and Equity 150M USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -302%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 5.77M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 60.3M shares +3.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.1M USD -47.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77M USD +29.1%
Deferred Tax Assets, Valuation Allowance 123M USD +22.2%
Deferred Tax Assets, Gross 127M USD +18%
Operating Lease, Liability 25.8M USD -12.7%
Depreciation 1.74M USD -20%
Payments to Acquire Property, Plant, and Equipment 7K USD -94.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -85.3M USD +27.9%
Lessee, Operating Lease, Liability, to be Paid 33.6M USD -15.6%
Property, Plant and Equipment, Gross 15.8M USD -14.5%
Operating Lease, Liability, Current 3.26M USD -0.12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.41M USD -8.72%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.92M USD +2.99%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.81M USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.87M USD -9.82%
Deferred Tax Assets, Operating Loss Carryforwards 68.3M USD +16.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.37M USD +43.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.02M USD
Operating Lease, Payments 6.3M USD +18.9%
Additional Paid in Capital 680M USD +2.69%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.28M USD +4.02%
Deferred Tax Assets, Net of Valuation Allowance 3.56M USD -46.1%
Share-based Payment Arrangement, Expense 17.1M USD -37.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%